Cargando…

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they...

Descripción completa

Detalles Bibliográficos
Autores principales: Brauneck, Franziska, Weimer, Pauline, Schulze zur Wiesch, Julian, Weisel, Katja, Leypoldt, Lisa, Vohwinkel, Gabi, Fritzsche, Britta, Bokemeyer, Carsten, Wellbrock, Jasmin, Fiedler, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606547/
https://www.ncbi.nlm.nih.gov/pubmed/34820398
http://dx.doi.org/10.3389/fmed.2021.763773
_version_ 1784602355628507136
author Brauneck, Franziska
Weimer, Pauline
Schulze zur Wiesch, Julian
Weisel, Katja
Leypoldt, Lisa
Vohwinkel, Gabi
Fritzsche, Britta
Bokemeyer, Carsten
Wellbrock, Jasmin
Fiedler, Walter
author_facet Brauneck, Franziska
Weimer, Pauline
Schulze zur Wiesch, Julian
Weisel, Katja
Leypoldt, Lisa
Vohwinkel, Gabi
Fritzsche, Britta
Bokemeyer, Carsten
Wellbrock, Jasmin
Fiedler, Walter
author_sort Brauneck, Franziska
collection PubMed
description Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they represent attractive effectors for immuno-therapeutic strategies with a better safety profile and a more favorable anti-tumor efficacy in comparison to conventional αβ T cells. Also, remarkable progress has been achieved re-activating exhausted T lymphocytes with inhibitors of co-regulatory receptors e.g., programmed cell death protein 1 (PD-1), T cell immunoreceptor with Ig and ITIM domains (TIGIT) and of the adenosine pathway (CD39, CD73). Regarding γδ T cells, little evidence is available. This study aimed to immunophenotypically characterize γδ T cells from patients with diagnosed acute myeloid leukemia (AML) in comparison to patients with multiple myeloma (MM) and healthy donors (HD). Methods: The frequency, differentiation, activation, and exhaustion status of bone marrow- (BM) derived γδ T cells from patients with AML (n = 10) and MM (n = 11) were assessed in comparison to corresponding CD4(+) and CD8(+) T cells and peripheral blood- (PB) derived γδ T cells from HDs (n = 16) using multiparameter flow cytometry. Results: BM-infiltrating Vδ1 T cells showed an increased terminally differentiated cell population (TEMRAs) in AML and MM in comparison to HDs with an aberrant subpopulation of CD27(−)CD45RA(++) cells. TIGIT, PD-1, TIM-3, and CD39 were more frequently expressed by γδ T cells in comparison to the corresponding CD4(+) T cell population, with expression levels that were similar to that on CD8(+) effector cells in both hematologic malignancies. In comparison to Vδ2 T cells, the increased frequency of PD-1(+)-, TIGIT(+)-, TIM-3(+), and CD39(+) cells was specifically observed on Vδ1 T cells and related to the TEMRA Vδ1 population with a significant co-expression of PD-1 and TIM-3 together with TIGIT. Conclusion: Our results revealed that BM-resident γδ T cells in AML and MM express TIGIT, PD-1, TIM-3 and CD39. As effector population for autologous and allogeneic strategies, inhibition of co-inhibitory receptors on especially Vδ1 γδ T cells may lead to re-invigoration that could further increase their cytotoxic potential.
format Online
Article
Text
id pubmed-8606547
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86065472021-11-23 Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma Brauneck, Franziska Weimer, Pauline Schulze zur Wiesch, Julian Weisel, Katja Leypoldt, Lisa Vohwinkel, Gabi Fritzsche, Britta Bokemeyer, Carsten Wellbrock, Jasmin Fiedler, Walter Front Med (Lausanne) Medicine Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they represent attractive effectors for immuno-therapeutic strategies with a better safety profile and a more favorable anti-tumor efficacy in comparison to conventional αβ T cells. Also, remarkable progress has been achieved re-activating exhausted T lymphocytes with inhibitors of co-regulatory receptors e.g., programmed cell death protein 1 (PD-1), T cell immunoreceptor with Ig and ITIM domains (TIGIT) and of the adenosine pathway (CD39, CD73). Regarding γδ T cells, little evidence is available. This study aimed to immunophenotypically characterize γδ T cells from patients with diagnosed acute myeloid leukemia (AML) in comparison to patients with multiple myeloma (MM) and healthy donors (HD). Methods: The frequency, differentiation, activation, and exhaustion status of bone marrow- (BM) derived γδ T cells from patients with AML (n = 10) and MM (n = 11) were assessed in comparison to corresponding CD4(+) and CD8(+) T cells and peripheral blood- (PB) derived γδ T cells from HDs (n = 16) using multiparameter flow cytometry. Results: BM-infiltrating Vδ1 T cells showed an increased terminally differentiated cell population (TEMRAs) in AML and MM in comparison to HDs with an aberrant subpopulation of CD27(−)CD45RA(++) cells. TIGIT, PD-1, TIM-3, and CD39 were more frequently expressed by γδ T cells in comparison to the corresponding CD4(+) T cell population, with expression levels that were similar to that on CD8(+) effector cells in both hematologic malignancies. In comparison to Vδ2 T cells, the increased frequency of PD-1(+)-, TIGIT(+)-, TIM-3(+), and CD39(+) cells was specifically observed on Vδ1 T cells and related to the TEMRA Vδ1 population with a significant co-expression of PD-1 and TIM-3 together with TIGIT. Conclusion: Our results revealed that BM-resident γδ T cells in AML and MM express TIGIT, PD-1, TIM-3 and CD39. As effector population for autologous and allogeneic strategies, inhibition of co-inhibitory receptors on especially Vδ1 γδ T cells may lead to re-invigoration that could further increase their cytotoxic potential. Frontiers Media S.A. 2021-11-08 /pmc/articles/PMC8606547/ /pubmed/34820398 http://dx.doi.org/10.3389/fmed.2021.763773 Text en Copyright © 2021 Brauneck, Weimer, Schulze zur Wiesch, Weisel, Leypoldt, Vohwinkel, Fritzsche, Bokemeyer, Wellbrock and Fiedler. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Brauneck, Franziska
Weimer, Pauline
Schulze zur Wiesch, Julian
Weisel, Katja
Leypoldt, Lisa
Vohwinkel, Gabi
Fritzsche, Britta
Bokemeyer, Carsten
Wellbrock, Jasmin
Fiedler, Walter
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
title Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
title_full Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
title_fullStr Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
title_full_unstemmed Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
title_short Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
title_sort bone marrow-resident vδ1 t cells co-express tigit with pd-1, tim-3 or cd39 in aml and myeloma
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606547/
https://www.ncbi.nlm.nih.gov/pubmed/34820398
http://dx.doi.org/10.3389/fmed.2021.763773
work_keys_str_mv AT brauneckfranziska bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT weimerpauline bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT schulzezurwieschjulian bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT weiselkatja bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT leypoldtlisa bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT vohwinkelgabi bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT fritzschebritta bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT bokemeyercarsten bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT wellbrockjasmin bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma
AT fiedlerwalter bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma